Tag: (nipocalimab)shows

IMAAVY (nipocalimab)shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
Health

IMAAVY (nipocalimab)shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions…

GlobeNews Wire
GlobeNews Wire